AbbVie will headline a fireside chat at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026. Management is scheduled for a 10:15 a.m. Central time session, during which executives will outline 2026 R&D priorities across immunology, oncology, neuroscience and eye care. A live audio webcast will stream via AbbVie’s Investor Relations site, with an archived replay available later that day. Investors will be watching for commentary on the integration of the Allergan Aesthetics portfolio, where AbbVie reported a 15% year-over-year revenue increase in Q3 2025.

In 2025 AbbVie outpaced the S&P 500 Health Care index by 320 basis points, driven by 12% organic revenue growth and an 8-cent per share earnings surprise in Q4. However, forward P/E sits at 20.3x compared with the 18.1x sector average, raising valuation concerns. Upcoming Most Favored Nation (MFN) drug-pricing agreements are projected to reduce gross margins by roughly 150 basis points in 2026. Meanwhile, broader markets have rotated toward cyclicals—up 18% year-to-date—while defensive healthcare names have been flat, suggesting that short-term share-price performance could lag until margin pressures ease and new pipeline data readouts bolster investor confidence.